New malaria vaccine trial could stop recurring fever in its tracks
NCT ID NCT07373301
First seen Jan 31, 2026 · Last updated May 16, 2026 · Updated 18 times
Summary
This study tests an experimental malaria vaccine called PvCS/Montanide ISA-51 in 72 healthy adults aged 18-50 in Colombia. The vaccine aims to protect against Plasmodium vivax, a parasite that causes repeated bouts of fever and illness. Participants receive three shots over four months, then are exposed to infected mosquito bites under medical supervision to see if the vaccine prevents infection. The trial checks safety and immune responses, with results expected to guide future larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA PREVENTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Malaria Vaccine and Drug Development Center (MVDC)
Cali, Valle del Cauca Department, 61000, Colombia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.